PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

First patients enrolled for Priothera’s mocravimod trial

Treatment is a maintenance therapy for certain patients with acute myeloid leukaemia

Priothera – a company focused on the development of a sphingosine 1 phosphate (S1P) receptor modulator compound – announced that the first patients have been enrolled in its MO-TRANS phase 2b/3 study evaluating mocravimod. It involves acute myeloid leukaemia (AML) patients undergoing allogeneic haematopoietic cell transplant (HCT).

Mocravimod is a S1P receptor modulator which has been previously tested in multiple autoimmune indications and is being developed to enhance the curative potential of allogeneic HCT. Meanwhile, the therapy has shown a clinically relevant benefit in an early clinical study in patients with haematologic malignancies undergoing allogeneic HCT.

Priothera is now initiating the pivotal MO-TRANS global phase 2b/3 study in Europe, Israel, the US and in additional Asian and Latin American countries. This will assess the safety and efficacy of mocravimod as an adjunctive and maintenance therapy in AML patients undergoing allogeneic HCT.

The double-blind study assesses relapse-free and overall survival of two dose levels of mocravimod in comparison to the placebo. Top-line data from this study is expected during 2025.

Marcos de Lima, a principal investigator for the trial, commented: “We are excited to be part of the important MO-TRANS global phase 2b/3 study to investigate mocravimod, a potential new adjunctive and maintenance therapy for patients with AML undergoing allogeneic HCT.”

He added: “Maintenance therapy is fast becoming the new frontier in the treatment of AML and we are committed to bringing forth new innovative therapies to AML patients.”

Florent Gros, co-founder and chief executive officer of Priothera, concluded: “Having successfully enrolled the first AML patients undergoing allogeneic HCT in our MO-TRANS global study represents a significant milestone for Priothera as we believe mocravimod has the potential to address a significant unmet need. Furthermore, we anticipate a strong uptake in patient enrolment with a significant number of patients currently being identified. We look forward to seeing top-line results in 2025.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026